GeoVax Labs, Inc.GOVXEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
GeoVax is a clinical-stage biotechnology company which develops vaccines. GeoVax's development platform uses Modified Vaccinia Ankara (MVA) vector technology, with improvements to antigen design and manufacturing capabilities. GeoVax uses recombinant DNA or recombinant viruses to produce virus-like particles (VLPs) in the person being vaccinated.
GOVX Q3 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-6.4M
Net Profit
$-6.3M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.31
GeoVax Labs, Inc. Q3 FY2025 Financial Summary
GeoVax Labs, Inc. reported revenue of $0 for Q3 FY2025, with a net profit of $-6.3M (down 8.7% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-6.3M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2025 |
GeoVax Labs, Inc. Quarterly Revenue & Net Profit History
GeoVax Labs, Inc. results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $0 | — | $-6.3M | N/A |
| Q2 FY2025 | $852.3K | +183.5% | $-5.4M | -630.0% |
| Q1 FY2025 | $1.6M | — | $-5.4M | -327.3% |
| Q3 FY2024 | $2.8M | — | $-5.8M | -208.5% |
| Q1 FY2024 | $0 | — | $-5.9M | N/A |
Income Statement
| Q1 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $2.8M | $1.6M | $852282 | $0 |
| YoY Growth | N/A | N/A | N/A | 183.5% | N/A |
Balance Sheet
| Q1 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|
| Assets | $3.4M | $11.1M | $10.8M | $5.4M | $6.7M |
| Liabilities | $3.3M | $2.6M | $2.9M | $2.5M | $1.8M |
| Equity | $54275 | $8.5M | $7.9M | $2.8M | $4.9M |
Cash Flow
| Q1 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|
| Operating CF | $-5.7M | $-9.3M | $-6.0M | $-4.3M | $-6.2M |